Published in J Neurol Neurosurg Psychiatry on December 16, 2010
Neurological involvement in primary Sjögren syndrome: a focus on central nervous system. PLoS One (2014) 1.02
Sjögren syndrome. CMAJ (2014) 0.88
Clinical features of autoimmune autonomic ganglionopathy and the detection of subunit-specific autoantibodies to the ganglionic acetylcholine receptor in Japanese patients. PLoS One (2015) 0.87
Relation of sensory peripheral neuropathy in Sjögren syndrome to anti-Ro/SSA. J Clin Rheumatol (2012) 0.85
Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity. Neurotherapeutics (2016) 0.79
Use of a novel high-resolution magnetic resonance neurography protocol to detect abnormal dorsal root Ganglia in Sjögren patients with neuropathic pain: case series of 10 patients and review of the literature. Medicine (Baltimore) (2014) 0.75
Movement and Other Neurodegenerative Syndromes in Patients with Systemic Rheumatic Diseases: A Case Series of 8 Patients and Review of the Literature. Medicine (Baltimore) (2015) 0.75
Peripheral neuropathies in rheumatic disease--a guide to diagnosis. Nat Rev Rheumatol (2012) 0.75
Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol (2008) 3.59
The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med (2005) 3.26
Inflammatory muscle diseases. N Engl J Med (2015) 3.15
Clinical manifestations and early diagnosis of Sjögren syndrome. Arch Intern Med (2004) 3.03
Treatment of primary Sjögren syndrome: a systematic review. JAMA (2010) 2.37
Cognitive impairment is related to increased arterial stiffness and microvascular damage in patients with never-treated essential hypertension. Am J Hypertens (2009) 2.24
Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain (2008) 2.18
Beta-amyloid is a substrate of autophagy in sporadic inclusion body myositis. Ann Neurol (2007) 2.18
Antiphospholipid syndrome (APS) nephropathy in catastrophic, primary, and systemic lupus erythematosus-related APS. J Rheumatol (2008) 2.05
Parkinson's disease associated with myasthenia gravis and rheumatoid arthritis. Neurol Sci (2014) 2.00
Morbidity, mortality, and organ damage in patients with antiphospholipid syndrome. J Rheumatol (2012) 1.97
Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med (2005) 1.93
Sjögren's syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjögren's syndrome. Arthritis Rheum (2004) 1.92
Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum (2004) 1.87
Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis (2007) 1.83
Properties and function of polyreactive antibodies and polyreactive antigen-binding B cells. J Autoimmun (2007) 1.71
Muscle and neuronal nicotinic acetylcholine receptors. Structure, function and pathogenicity. FEBS J (2007) 1.68
Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution. Am J Med (2007) 1.64
Tragedy in a heartbeat: malfunctioning desmin causes skeletal and cardiac muscle disease. J Clin Invest (2009) 1.63
Phenotypic spectrum of disorders associated with glycyl-tRNA synthetase mutations. Brain (2005) 1.63
Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. Neurology (2006) 1.62
Pattern and distribution of myocardial fibrosis in systemic sclerosis: a delayed enhanced magnetic resonance imaging study. Arthritis Rheum (2007) 1.62
High definition profiling of autoantibodies to glutamic acid decarboxylases GAD65/GAD67 in stiff-person syndrome. Biochem Biophys Res Commun (2007) 1.60
Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum (2002) 1.59
{beta}2 Glycoprotein I ({beta}2GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome. Blood (2009) 1.47
Upregulation of antiphospholipid antibodies following cyclophosphamide therapy in patients with systemic lupus erythematosus. J Rheumatol (2008) 1.47
Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol (2011) 1.47
Classification criteria for Sjogren's syndrome: a critical review. J Autoimmun (2011) 1.46
Salivary gland epithelial cell exosomes: A source of autoantigenic ribonucleoproteins. Arthritis Rheum (2005) 1.45
Pathogenetic mechanisms in the initiation and perpetuation of Sjögren's syndrome. Nat Rev Rheumatol (2010) 1.43
Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virus-unrelated cryoglobulinaemic vasculitis. Clin Exp Rheumatol (2012) 1.41
Characteristics of the minor salivary gland infiltrates in Sjögren's syndrome. J Autoimmun (2009) 1.39
Longterm followup after tapering mycophenolate mofetil during maintenance treatment for proliferative lupus nephritis. J Rheumatol (2011) 1.39
Asymptomatic avascular necrosis in patients with primary antiphospholipid syndrome in the absence of corticosteroid use: a prospective study by magnetic resonance imaging. Arthritis Rheum (2003) 1.38
The geoepidemiology of Sjögren's syndrome. Autoimmun Rev (2009) 1.37
Analysis of GAD65 autoantibodies in Stiff-Person syndrome patients. J Immunol (2005) 1.35
Pathogenesis of Sjögren's syndrome: what we know and what we should learn. J Autoimmun (2012) 1.35
Paraneoplastic anti-NMDAR encephalitis: long term follow-up reveals persistent serum antibodies. J Neurol (2011) 1.29
Evidence for coxsackievirus infection in primary Sjögren's syndrome. Arthritis Rheum (2004) 1.29
Drug Insight: the use of intravenous immunoglobulin in neurology--therapeutic considerations and practical issues. Nat Clin Pract Neurol (2007) 1.28
Guidelines for the diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst (2003) 1.26
Hypoglycosylation of alpha-dystroglycan in patients with hereditary IBM due to GNE mutations. Mol Genet Metab (2004) 1.26
Blood leptin and adiponectin as possible mediators of the relation between fat mass and BMD in perimenopausal women. J Bone Miner Res (2004) 1.26
Immunology of stiff person syndrome and other GAD-associated neurological disorders. Expert Rev Clin Immunol (2013) 1.24
Anticentromere antibody positive Sjögren's Syndrome: a retrospective descriptive analysis. Arthritis Res Ther (2010) 1.23
Foxp3+ T-regulatory cells in Sjogren's syndrome: correlation with the grade of the autoimmune lesion and certain adverse prognostic factors. Am J Pathol (2008) 1.23
Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum (2006) 1.21
Topical and systemic medications for the treatment of primary Sjögren's syndrome. Nat Rev Rheumatol (2012) 1.19
Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen β2-glycoprotein I. Arthritis Rheum (2011) 1.18
Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum (2009) 1.17
Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol (2002) 1.17
Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) (2009) 1.17
Anti-glutamic acid decarboxylase antibodies in the serum and cerebrospinal fluid of patients with stiff-person syndrome: correlation with clinical severity. Arch Neurol (2004) 1.16
Toll-like receptor-4 is up-regulated in hematopoietic progenitor cells and contributes to increased apoptosis in myelodysplastic syndromes. Clin Cancer Res (2007) 1.16
Sjögren's syndrome--study of autoantigens and autoantibodies. Clin Rev Allergy Immunol (2007) 1.16
GNE mutations in an American family with quadriceps-sparing IBM and lack of mutations in s-IBM. Neurology (2002) 1.15
Classification criteria for Sjogren's syndrome: we actually need to definitively resolve the long debate on the issue. Ann Rheum Dis (2012) 1.14
Variable pathogenic potentials of mutations located in the desmin alpha-helical domain. Hum Mutat (2006) 1.14
The management of Sjögren's syndrome. Nat Clin Pract Rheumatol (2006) 1.12
Sjögren's syndrome. Annu Rev Pathol (2013) 1.10
Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proc Natl Acad Sci U S A (2012) 1.10
Prognosis and outcome of non-Hodgkin lymphoma in primary Sjögren syndrome. Medicine (Baltimore) (2012) 1.09
Idiotype-anti-idiotype circuit in non-autoimmune mice after immunization with the epitope and complementary epitope 289-308aa of La/SSB: implications for the maintenance and perpetuation of the anti-La/SSB response. J Autoimmun (2003) 1.09
Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits. Clin Ophthalmol (2011) 1.08
Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. J Autoimmun (2006) 1.07
Exome sequencing identifies titin mutations causing hereditary myopathy with early respiratory failure (HMERF) in families of diverse ethnic origins. BMC Neurol (2013) 1.07
Intravenous immune globulin in hereditary inclusion body myopathy: a pilot study. BMC Neurol (2007) 1.07
Selective screening of secretory vesicle-associated proteins for autoantigens in type 1 diabetes: VAMP2 and NPY are new minor autoantigens. Clin Immunol (2008) 1.06
Conventional therapy of Sjogren's syndrome. Clin Rev Allergy Immunol (2007) 1.05
Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study. Arthritis Res Ther (2011) 1.04
Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol (2003) 1.04
A series of West European patients with severe cardiac and skeletal myopathy associated with a de novo R406W mutation in desmin. J Neurol (2004) 1.03
Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens. Clin Ther (2008) 1.02
Structural and functional mutations of the perlecan gene cause Schwartz-Jampel syndrome, with myotonic myopathy and chondrodysplasia. Am J Hum Genet (2002) 1.02
Inflammatory Muscle Diseases. N Engl J Med (2015) 1.01
Autoantibodies to intracellular autoantigens and their B-cell epitopes: molecular probes to study the autoimmune response. Crit Rev Clin Lab Sci (2006) 1.00
The liver in brucellosis. Clin Gastroenterol Hepatol (2007) 1.00
Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum (2006) 0.99
Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus. J Rheumatol (2002) 0.98
Wound healing: immunological aspects. Injury (2006) 0.98
Unmasking the anti-La/SSB response in sera from patients with Sjogren's syndrome by specific blocking of anti-idiotypic antibodies to La/SSB antigenic determinants. Mol Med (2002) 0.98
Use of a cell-free system to determine UDP-N-acetylglucosamine 2-epimerase and N-acetylmannosamine kinase activities in human hereditary inclusion body myopathy. Glycobiology (2005) 0.98
Autoimmunity to GABAA-receptor-associated protein in stiff-person syndrome. Brain (2006) 0.98
Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings. Arch Intern Med (2006) 0.98
Practical considerations on the use of rituximab in autoimmune neurological disorders. Ther Adv Neurol Disord (2010) 0.98
Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity. Brain (2004) 0.97
Hepatitis C virus, Sjögren's syndrome and B-cell lymphoma: linking infection, autoimmunity and cancer. Autoimmun Rev (2005) 0.97
Glycine receptor antibodies in stiff-person syndrome and other GAD-positive CNS disorders. Neurology (2013) 0.97
In-frame deletion in the seventh immunoglobulin-like repeat of filamin C in a family with myofibrillar myopathy. Eur J Hum Genet (2008) 0.97
Mucosa-associated lymphoid tissue lymphoma in Sjögren's syndrome: risks, management, and prognosis. Rheum Dis Clin North Am (2008) 0.97